My Dashboard
Fin. Planning
Our Solutions
Stocks
Funds
Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
BSE: 539523 | NSE: ALKEM | Pharmaceuticals & Drugs | Mid Cap
1. Is Alkem Laboratories Ltd a good quality company?
Past 10 year's financial track record analysis by Moneyworks4me indicates that Alkem Laboratories Ltd is a good quality company.
2. Is Alkem Laboratories Ltd undervalued or overvalued?
The key valuation ratios of Alkem Laboratories Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
3. Is Alkem Laboratories Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Alkem Laboratories Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘValue Creation Index Colour Code Guide ⓘ |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | |||
| ROCE % ⓘ | 13.7% | 10.4% | 18.3% | 20.6% | 14.6% | 14.1% | 19% | 20.4% | 15.5% | 11% | - | ||
| Value Creation Index ⓘ | 0.2 | -0.1 | 0.4 | 0.8 | 0.3 | 0.3 | 0.7 | 0.8 | 0.4 | 0.0 | - | ||
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ |
|||||||||||||
| Sales ⓘ | 2,708 | 3,138 | 3,859 | 4,548 | 5,281 | 5,714 | 6,677 | 7,220 | 8,830 | 9,055 | 9,249 | ||
| YoY Gr. Rt. % | - | 15.9% | 23% | 17.9% | 16.1% | 8.2% | 16.9% | 8.1% | 22.3% | 2.6% | - | ||
| Adj EPS ⓘ | 37.3 | 30.2 | 59.2 | 73.8 | 60.3 | 65.7 | 104.5 | 138 | 126.8 | 93.2 | 105.9 | ||
| YoY Gr. Rt. % | - | -19.1% | 96.4% | 24.7% | -18.3% | 9% | 59% | 32% | -8.1% | -26.5% | - | ||
| BVPS (₹) ⓘ | 233.4 | 259.4 | 301.1 | 367.4 | 408.7 | 457.2 | 525.3 | 637.9 | 731.4 | 782.1 | 804.7 | ||
| Adj Net Profit ⓘ | 445 | 360 | 708 | 883 | 721 | 786 | 1,250 | 1,650 | 1,516 | 1,114 | 1,266 | ||
| Cash Flow from Ops. ⓘ | 106 | 242 | 630 | 499 | 318 | 745 | 682 | 1,324 | 1,299 | 1,437 | - | ||
| Debt/CF from Ops. ⓘ | 9 | 4.6 | 0.6 | 0.7 | 1.7 | 0.7 | 1.8 | 1 | 1.7 | 0.8 | - | ||
CAGR ⓘCAGR Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 Years | 5 Years | 3 Years | 1 Years | |||||||||
| Sales ⓘ | 14.4% | 11.4% | 10.7% | 2.6% | ||||||||
| Adj EPS ⓘ | 10.7% | 9.1% | -3.8% | -26.5% | ||||||||
| BVPSⓘ | 14.4% | 13.9% | 14.2% | 6.9% | ||||||||
| Share Price | - | 11.8% | 7.8% | 8.8% | ||||||||
Key Financial Parameters ⓘPerformance Ratio Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | ||
| Return on Equity % ⓘ | 17.3 | 12.2 | 21.1 | 22.1 | 15.5 | 15.2 | 21.3 | 23.7 | 18.5 | 12.3 | 13.3 | |
| Op. Profit Mgn % ⓘ | 15.3 | 11.2 | 19 | 19.3 | 18.9 | 18.4 | 22.2 | 27 | 20.5 | 15.3 | 16.5 | |
| Net Profit Mgn % ⓘ | 16.5 | 11.5 | 18.4 | 19.4 | 13.7 | 13.8 | 18.7 | 22.9 | 17.2 | 12.3 | 13.7 | |
| Debt to Equity ⓘ | 0.3 | 0.4 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.3 | 0.1 | - | |
| Working Cap Days ⓘ | 185 | 206 | 180 | 155 | 162 | 159 | 156 | 176 | 178 | 184 | 0 | |
| Cash Conv. Cycle ⓘ | 54 | 53 | 41 | 41 | 45 | 51 | 62 | 76 | 80 | 81 | 0 | |
Sales growth is growing at healthy rate in last 3 years 10.69%
Return on Equity has declined versus last 3 years average to 13.30%
Net Profit has been subdued in last 3 years -3.75%
Sales growth is not so good in last 4 quarters at 7.61%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 105.9 | 95.6 |
| TTM Sales (₹ Cr.) | 9,249 | 11,991 |
| BVPS (₹.) ⓘ | 804.7 | 780.5 |
| Reserves (₹ Cr.) ⓘ | 9,597 | 9,309 |
| P/BV ⓘ | 4.41 | 4.55 |
| PE ⓘ | 33.48 | 37.13 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 2835.05 / 4270.95 |
| All Time Low / High (₹) | 1175.00 / 4270.95 |
| Market Cap (₹ Cr.) | 42,383 |
| Equity (₹ Cr.) | 23.9 |
| Face Value (₹) | 2 |
| Industry PE ⓘ | 41.7 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Alkem Laboratories is one of India’s largest generic and specialty pharmaceutical company. Also, it has consistently been ranked amongst the top ten pharmaceutical companies in India. Its portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, its dominance in anti-infective segment has remained unchallenged. Some part of its revenue is generated via offshore sales. The company has manufacturing facilities at multiple locations in India and the United States of America. Its upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries.
Business area of the company
The company is one of India’s foremost global pharmaceutical company. The company is engaged in the development, manufacture and marketing of pharmaceuticals with operational footprints across different countries. In India, it has a formidable presence in several therapy segments and consistently features amongst the top ten pharmaceutical companies. Steered by its industry experience of over four decades, it offers high-quality branded generics, generic drugs, active pharmaceutical ingredients and nutraceuticals.
Awards and Recognition
2016:
2017:
2018:
2019:
2020:
Milestones
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Download APP
